Navigation Links
Geneticure Awarded Patent for Precision Medicine Blood Pressure Treatment
Date:9/17/2019

Geneticure, Inc., a Rochester Minnesota company developing personalized medicine tests to improve success in chronic diseases, announces today that the U.S. Patent and Trademark Office (USPTO) and European Patent Office (EPO) have issued patents for their multi-gene combinatorial genetic algorithm to rank drug class recommendations for hypertension treatment.

The patent applies to Geneticure’s first pharmacogenomics test, in a pipeline that includes additional chronic disease panels. The Geneticure for Hypertension Pharmacogenomic Panel is the first of its kind to use multiple gene variants that have been weighted according to their impact on blood pressure response and include integration across organ systems and medication response.

The initial algorithm was formulated using a candidate-gene approach from hundreds of peer-reviewed studies that identify how subtle variations in the genetic code can influence which blood pressure medication will work most effectively, and with original research. The effectiveness of Geneticure’s assay was then assessed an optimized in multiple retrospective clinical trials that have demonstrated that a patient who is prescribed the medication ranked as the first recommendation by the algorithm had significantly lower blood pressure than a patient who did not match the recommendation.

“This is a major milestone for our company solidifying our unique cornerstones of personalized medicine: expertise in the genomics of integrative physiology, leading with powerful clinical and health economic evidence while coupled with strong intellectual property,” said Scott Snyder, co-founder and CEO of Geneticure.

About Geneticure: Geneticure Inc. is a leading personalized medicine company dedicated to the promise of using an individual’s genetics to help guide their treatment. Geneticure’s proprietary approach leverages a unique understanding for the integrative physiology in complex and chronic diseases. This allows Geneticure’s tests to be tailored for each specific disease and the underlying genetics influential to treatment response. An evidence-first company, Geneticure focuses on clinical research demonstrating improved outcomes and improved health-economics, supporting the shift from one-size-fits-all medicine to precision medicine. For more information, visit http://www.geneticure.com.

Read the full story at https://www.prweb.com/releases/geneticure_awarded_patent_for_precision_medicine_blood_pressure_treatment/prweb16575176.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. S&D Marketing Advertising Awarded WBENC Certification
2. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
3. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
4. BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
5. Selenium, Ltd. Awarded $500,000 SBIR Grant for Biofouling Prevention Technology
6. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
7. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
8. Empire Genomics Awarded SBIR Phase I Grant from NCI for Companion Diagnostics for Multiple Myeloma
9. University of Huddersfield awarded £93k award from the EPSRC
10. Puritan Awarded New Canadian Patent for PurFlock® Ultra Flocked Swab
11. ConfometRx Awarded Patent on GPCRs that Contain a Stabilizing IC2 Fusion Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2020)... ... February 19, 2020 , ... ... for the life sciences industry, today announced the opening of a new office ... Partner, Red Nucleus R&D. , Red Nucleus announced the new office in response ...
(Date:2/11/2020)... ... February 11, 2020 , ... ... in North America, today announced that the City of Fort Worth has partnered ... management needs. Commencing in April of 2020, Synagro will assume operation of the ...
(Date:2/5/2020)... (PRWEB) , ... February 05, 2020 , ... Rare ... observance, sponsored by The National Organization for Rare Disorders (NORD), to raise awareness amongst ... ( rarediseaseday.org ). The Balancing Act’s “Behind The Mystery” rare disease series ...
(Date:1/28/2020)... (PRWEB) , ... January 28, 2020 , ... ... to be the exclusive distributor to food and beverage manufactures within North America. ... considered critical suppliers. This agreement will allow each company to pool their collective ...
Breaking Biology Technology:
(Date:3/10/2020)... DIEGO (PRWEB) , ... March 10, 2020 , ... ... has joined Cytonus’ Board of Directors. Dr. Narasimhan is Senior Vice President of ... “On behalf of the Board of Directors of Cytonus, we are extremely pleased ...
(Date:3/5/2020)... (PRWEB) , ... March 05, 2020 , ... Patients in ... same-day dental implants from Dr. Nickelice Brand of Dental Implants of Ocala. Same-day ... to get an entirely new smile in just one day. This treatment utilizes advanced ...
(Date:3/4/2020)... , ... March 04, 2020 , ... ... and CEOs to apply to the MedTech IGNITE program’s 2020 IGNITE Cohort. The ... networking curriculum to attract and nurture the next generation of medtech founders and ...
Breaking Biology News(10 mins):